The impact of the tumor genotype on the efficacy of oncolytic HSVs was reported in independent observations, for example in the mitogen-activated protein kinase kinase –protein kinase R (MEK-PKR) pathway during the infection with Δγ134.5 oHSVs [48]. This evidence concerns the gene WNK2 and neoplasm.